Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Neuroinflammation and functional connectivity in Alzheimer's disease: interactive influences on cognitive performance.

Passamonti L, Tsvetanov KA, Jones PS, Bevan-Jones WR, Arnold R, Borchert RJ, Mak E, Su L, O'Brien JT, Rowe JB.

J Neurosci. 2019 Jul 18. pii: 2574-18. doi: 10.1523/JNEUROSCI.2574-18.2019. [Epub ahead of print]

PMID:
31320450
2.

In vivo evidence for pre-symptomatic neuroinflammation in a MAPT mutation carrier.

Bevan-Jones WR, Cope TE, Jones PS, Passamonti L, Hong YT, Fryer T, Arnold R, Coles JP, Aigbirhio FI, O'Brien JT, Rowe JB.

Ann Clin Transl Neurol. 2019 Jan 2;6(2):373-378. doi: 10.1002/acn3.683. eCollection 2019 Feb.

3.

Early microglial activation and peripheral inflammation in dementia with Lewy bodies.

Surendranathan A, Su L, Mak E, Passamonti L, Hong YT, Arnold R, Vázquez Rodríguez P, Bevan-Jones WR, Brain SAE, Fryer TD, Aigbirhio FI, Rowe JB, O'Brien JT.

Brain. 2018 Dec 1;141(12):3415-3427. doi: 10.1093/brain/awy265.

4.

Dissociable effects of acute SSRI (escitalopram) on executive, learning and emotional functions in healthy humans.

Skandali N, Rowe JB, Voon V, Deakin JB, Cardinal RN, Cormack F, Passamonti L, Bevan-Jones WR, Regenthal R, Chamberlain SR, Robbins TW, Sahakian BJ.

Neuropsychopharmacology. 2018 Dec;43(13):2645-2651. doi: 10.1038/s41386-018-0229-z. Epub 2018 Sep 26.

5.

[11C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy.

Passamonti L, Rodríguez PV, Hong YT, Allinson KSJ, Bevan-Jones WR, Williamson D, Jones PS, Arnold R, Borchert RJ, Surendranathan A, Mak E, Su L, Fryer TD, Aigbirhio FI, O'Brien JT, Rowe JB.

Neurology. 2018 May 29;90(22):e1989-e1996. doi: 10.1212/WNL.0000000000005610. Epub 2018 Apr 27.

6.

Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy.

Cope TE, Rittman T, Borchert RJ, Jones PS, Vatansever D, Allinson K, Passamonti L, Vazquez Rodriguez P, Bevan-Jones WR, O'Brien JT, Rowe JB.

Brain. 2018 Feb 1;141(2):550-567. doi: 10.1093/brain/awx347.

7.

[18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia.

Bevan-Jones WR, Cope TE, Jones PS, Passamonti L, Hong YT, Fryer TD, Arnold R, Allinson KSJ, Coles JP, Aigbirhio FI, Patterson K, O'Brien JT, Rowe JB.

J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1032-1037. doi: 10.1136/jnnp-2017-316402. Epub 2017 Sep 14.

8.

18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.

Passamonti L, Vázquez Rodríguez P, Hong YT, Allinson KS, Williamson D, Borchert RJ, Sami S, Cope TE, Bevan-Jones WR, Jones PS, Arnold R, Surendranathan A, Mak E, Su L, Fryer TD, Aigbirhio FI, O'Brien JT, Rowe JB.

Brain. 2017 Mar 1;140(3):781-791. doi: 10.1093/brain/aww340.

9.

[18F]AV-1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation.

Bevan Jones WR, Cope TE, Passamonti L, Fryer TD, Hong YT, Aigbirhio F, Kril JJ, Forrest SL, Allinson K, Coles JP, Simon Jones P, Spillantini MG, Hodges JR, O'Brien JT, Rowe JB.

Ann Clin Transl Neurol. 2016 Oct 18;3(12):940-947. doi: 10.1002/acn3.366. eCollection 2016 Dec.

10.

Multi-modal MRI investigation of volumetric and microstructural changes in the hippocampus and its subfields in mild cognitive impairment, Alzheimer's disease, and dementia with Lewy bodies.

Mak E, Gabel S, Su L, Williams GB, Arnold R, Passamonti L, Vazquez Rodríguez P, Surendranathan A, Bevan-Jones WR, Rowe JB, O'Brien JT.

Int Psychogeriatr. 2017 Apr;29(4):545-555. doi: 10.1017/S1041610216002143. Epub 2017 Jan 16.

11.

Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses.

Bevan-Jones WR, Surendranathan A, Passamonti L, Vázquez Rodríguez P, Arnold R, Mak E, Su L, Coles JP, Fryer TD, Hong YT, Williams G, Aigbirhio F, Rowe JB, O'Brien JT.

BMJ Open. 2017 Jan 7;7(1):e013187. doi: 10.1136/bmjopen-2016-013187.

12.

Reply: Suicidality in Huntington's Disease: Distinguishing lithium from other psychotropic medications.

Moulton CD, Hopkins CW, Bevan-Jones WR.

Mov Disord. 2015 Sep;30(10):1438-9. doi: 10.1002/mds.26268. Epub 2015 May 23. No abstract available.

PMID:
26010142
13.

Systematic review of pharmacological treatments for depressive symptoms in Huntington's disease.

Moulton CD, Hopkins CW, Bevan-Jones WR.

Mov Disord. 2014 Oct;29(12):1556-61. doi: 10.1002/mds.25980. Epub 2014 Aug 11. Review.

PMID:
25111961

Supplemental Content

Loading ...
Support Center